Molecular profiling of plasma from matched NCI-MATCH gynecological cancers.
Amanda Peach(Frederick National Laboratory for Cancer Research), Chris Karlovich(Clovis Oncology (United States)), Peter J. O’Dwyer(University of Pennsylvania), Rini Pauly(Frederick National Laboratory for Cancer Research), P. Mickey Williams(National Cancer Institute), Jennifer S. LoCoco(Illumina (United States)), Traci Pawlowski(Illumina (United States)), James H. Doroshow(National Cancer Institute), Vishnuprabha Rahul Kannan(Frederick National Laboratory for Cancer Research), Alice P. Chen(National Institutes of Health), Lisa McShane(National Cancer Institute), Naoko Takebe(National Cancer Institute), Bao T. Le(University of Wisconsin–Madison), Eric Greenbank(Frederick National Laboratory for Cancer Research), Biswajit Das(Frederick National Laboratory for Cancer Research), Ting-Chia Chang(Frederick National Laboratory for Cancer Research), Li Chen(Frederick National Laboratory for Cancer Research), Lyndsay N. Harris(National Institutes of Health)
Cited by 1
Related Papers
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
|New England Journal of Medicine|2010|3.5k
Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200
|Journal of Clinical Oncology|2007|2.3k
Molecular Definition of Breast Tumor Heterogeneity
|Cancer Cell|2007|1.4k
Changes in circulating microRNA levels associated with prostate cancer
|British Journal of Cancer|2012|717
Rociletinib in <i>EGFR</i>-Mutated Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2015|664